In a double-blind trial of 144 advanced cancer patients, a 1:1 THC:CBD oil didn't improve overall symptom burden over palliative care alone—though pain scores specifically did improve.
Cancer patients considering medicinal cannabis, oncologists fielding cannabis questions, and palliative care researchers.
What the researchers found
This is one of the most rigorous tests of medicinal cannabis for cancer symptoms conducted to date. Patients with advanced cancer were randomized to either a 1:1 THC:CBD oil or placebo, dose-escalated over 14 days, and continued to day 28—all while receiving standard palliative care.
The primary outcome was total symptom distress, measured by summing scores across multiple symptoms (pain, fatigue, nausea, depression, anxiety, drowsiness, appetite, wellbeing, and shortness of breath). Both groups improved over time, but there was no difference between cannabis and placebo. The improvement in both arms likely reflects the benefits of palliative care itself.
However, one secondary finding stood out: ESAS pain scores improved significantly more in the cannabis arm than in placebo (mean change −1.42 vs. −0.46, p = 0.04). This is a modest but statistically significant difference, suggesting cannabis may have a specific analgesic effect even when it doesn't improve the overall symptom picture.
The study design was strong—double-blind, placebo-controlled, with a pre-planned sample size that was met. The null result for overall symptoms is meaningful precisely because the trial was well-powered to detect a difference if one existed.
Why it matters
Many cancer patients use or want to use cannabis for symptom relief, often based on anecdotal reports. This trial provides high-quality evidence that while cannabis may help specifically with pain, it doesn't improve the overall symptom burden beyond what good palliative care provides. That's important information for patients making treatment decisions and for oncologists being asked about cannabis.
The numbers in context
N = 144 randomized (120 reached day 14 per pre-planned sample size). Total symptom distress: −6.30 cannabis vs. −6.98 placebo (p = 0.76, no difference). ESAS pain: −1.42 cannabis vs. −0.46 placebo (p = 0.04, significant).
How the study worked
Double-blind, placebo-controlled randomized clinical trial. 144 patients with advanced cancer randomized to medicinal cannabis (1:1 THC:CBD at 10 mg/ml) or placebo oil. Dose escalated over 14 days based on tolerance and efficacy, continued to day 28. Primary outcome: change in Total Symptom Distress Score (TSDS) at day 14 using the Edmonton Symptom Assessment Scale. Multiple secondary outcomes including individual symptoms, opioid use, quality of life, and global impression of change.
Who was studied
N=144 adults aged 18-80+, 50% female, patients with advanced cancer in Australia.
What this study cannot tell us
28-day trial duration may be too short for some benefits to emerge. The 1:1 THC:CBD ratio and oil formulation may not represent all cannabis products—different ratios, inhaled routes, or higher doses might produce different results. Both groups improved substantially, making it harder to detect additional cannabis benefit. Pain finding was a secondary outcome.
How to read the evidence
Double-blind, placebo-controlled randomized trial that met its pre-planned sample size—the gold standard for clinical evidence.
When this study was published
Published in 2025 with current clinical protocols and cannabis formulations.
The bigger picture
This connects to RTHC-00161's finding that medical marijuana laws were associated with reduced opioid prescriptions after cancer surgery. Together, they suggest cannabis may play a specific role in cancer pain management—but not as a general symptom cure-all. The pain-specific benefit aligns with the broader pain literature on cannabinoids, while the null result for other symptoms echoes the mixed evidence for cannabis in nausea, appetite, and mood.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Would a longer trial or different THC:CBD ratio show broader symptom benefits? Is the pain-specific effect large enough to be clinically meaningful for patients? Could cannabis reduce opioid requirements in this population even if it doesn't improve overall symptoms?
Read the original research
Medicinal cannabis for symptom control in advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33(8), 715
Supportive Care in Cancer is a reputable journal focusing on research related to cancer care and symptom management.
Citation
Hardy, Janet R; Greer, Ristan M; Pelecanos, Anita M; Huggett, Georgie E; Kearney, Alison M; Gurgenci, Taylan H; Good, Phillip D. (2025). Medicinal cannabis for symptom control in advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33(8), 715. https://doi.org/10.1007/s00520-025-09763-5
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk